Roth Capital Positive on Ligand Pharma (LGND); Kyprolis Met Primary Endpoint in ENDEAVOR Trial (AMGN)
Tweet Send to a Friend
Roth Capital affirms Ligand Pharma (Nasdaq: LGND) with a Buy rating and $116 price target after partner Amgen (Nasdaq: AMGN) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
